drugset / Trial / NCT02213289
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.
Timeline
- Start
- 2015-01-20
- Primary completion
- 2020-02-01
- Completion
- 2020-08-20
Outcome
Met primary endpoint
registry analysis (superiority test); ITT-PTS: Personalized Treatment Strategy; p = 0.0024; One-sided Z-test NCT02213289 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemarituzumab | Monoclonal antibody | — | — |
| Subject | DEPATUXIZUMAB | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Ramucirumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |